European Patent Office intends to grant patent for Allarity's DRP companion diagnostic for stenoparib

Allarity Therapeutics, Inc.

EPO issued formal notice of intention to grant patent for DRP companion diagnostic for stenoparib, a PARP/Tankyrase inhibitor.
Patent covers use of DRP to identify cancer patients most likely to benefit from stenoparib treatment.
Patent applications for Stenoparib DRP also pending in US, Japan, China, Australia, and India.
Allarity now has 17 granted DRP patents, including 8 in the US, strengthening its intellectual property portfolio.
CEO Thomas Jensen stated the patent is key for securing international market position ahead of potential commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.